BioMedTech Press Release

France 2030 : Truffle Capital is on board with Spikimm

Spikimm, created by Truffle Capital, is the winner via its AMIBAB project of the call for expressions of interest "Emerging Infectious Diseases and CBRN Threats" as part of the France 2030 initiative.

For information, Government's plan named "France 2030", aims to being prepared for future pandemics and to ensure that the country has all the necessary ressources.

At the heart of the fight against emerging infectious diseases, SpikImm, created by Truffle Capital and spin-off of the Institut Pasteur, is one of the winners of the "Emerging Infectious Diseases and CBRN Threats" plan, with its AMIMAB project.

AMIMAB project aims to develop potent monoclonal antibodies that are active against several SARS-CoV-2 variants, including Omicron. Their efficacy has been demonstrated in in-vitro and animal tests. SpikImm wants to accelerate their international preclinical and clinical development so that they can be used in the fight against Covid-19 pandemic, notably as a preventive "pre-exposure prophylaxis" use in immunocompromised patients who are not responding to vaccines. With 15 million people in Europe and the United States affected, this represents a critical medical need. The project intends to provide an easy-to-administer application (subcutaneous or intramuscular).

Scientific team involved: Humoral Immunity Laboratory (UMR Inserm/Pasteur) directed by Hugo Mouquet